RT Journal Article SR Electronic T1 p27kip1 and Ki-67 (MIB1) Immunohistochemical Expression in Radical Prostatectomy Specimens of Patients with Clinically Localized Prostate Cancer JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 911 OP 920 VO 19 IS 5 A1 REVELOS, KYRIAKOS A1 PETRAKI, CONSTANTINA A1 GREGORAKIS, ALKIVIADIS A1 SCORILAS, ANDREAS A1 PAPANASTASIOU, PANAGIOTIS A1 TENTA, ROXANE A1 KOUTSILIERIS, MICHAEL YR 2005 UL http://iv.iiarjournals.org/content/19/5/911.abstract AB The immunohistochemical expressions (IE) of p27kip1 and Ki-67 (MIB-1), both involved in cell cycle regulation and cell proliferation, and their ability to predict biochemical failure, were assessed in patients with clinically localized prostate cancer who had underdone radical prostatectomy of curative intent. In addition, p27kip1 and Ki-67 (MIB1) expressions were correlated with several pre-operative and post-operative parameters, such as Gleason score, extracapsular extension, seminal vesicle involvement, pelvic lymph nodes metastasis, positive surgical margins, coexistence of high-grade prostatic intraepithelial neoplasia, tumour size, prostate volume and PSA levels. Our analysis involved 130 consecutive radical prostatectomy specimens. A statistically significant correlation of low p27kip1 IE with seminal vesicles involvement, increased tumour volume and high pre-operative PSA values was documented. Low p27kip1 IE was significantly correlated with an increased likelihood of biochemical failure after radical prostatectomy. In addition, the increased IE of Ki-67 (MIB1) correlated significantly with metastatic disease in the pelvic lymph nodes and was a significant predictor of biochemical failure. Cox regression analysis, which included p27kip1 expression, Ki-67 (MIB1) expression and all the pre-operative and post-operative parameters, showed that pelvic lymph node involvement and Ki-67 (MIB1) IE were independent prognostic markers of biochemical failure after radical prostatectomy. Copyright © 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved